Lyra Therapeutics Inc
NASDAQ:LYRA
Lyra Therapeutics Inc
NASDAQ:LYRA
Price:
0.3622 USD
1.8%
Market Closed
Updated:
May 16, 2024
Lyra Therapeutics Inc
Cash from Operating Activities
|
Lyra Therapeutics Inc
Cash from Operating Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
Cash from Operating Activities
-$63.3m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$23.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$14.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
See Also
What is Lyra Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-63.3m
USD
-63.3m
USD
Based on the financial report for Dec 31, 2023, Lyra Therapeutics Inc's Cash from Operating Activities amounts to -63.3m USD.
What is Lyra Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-57%
-57%
Over the last year, the Cash from Operating Activities growth was -46%. The average annual Cash from Operating Activities growth rates for Lyra Therapeutics Inc have been -44% over the past three years , -57% over the past five years .
You don't have any saved screeners yet
